LFMD LIFEMD INC

LifeMD to Participate in Upcoming Investor Conferences and Panel Discussions

LifeMD to Participate in Upcoming Investor Conferences and Panel Discussions

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in two upcoming investor conferences and a panel discussion.

  • Cantor Fitzgerald GLP-1 Panel: Payor vs. Provider Perspective, November 13, 2023. Justin Schreiber, Chief Executive Officer of LifeMD, will participate in a panel discussion with Andrew Baskin, M.D., Independent Consultant and formerly the Vice President, National Medical Director at Aetna, Inc. regarding their perspectives on GLP-1s.

  • BTIG Digital Health Forum, November 21, 2023. Mr. Schreiber will participate in a panel discussion titled “Using the Platform Approach” at 12:00 p.m. Eastern time and will be available for one-on-one virtual meetings.

  • Sidoti’s Small-Cap Virtual Conference, December 6-7, 2023. Management will be presenting a corporate overview and will be hosting one-on-one meetings with investors. To register for the conference, visit . Registration is free and investors are not required to be a Sidoti client.

About LifeMD, Inc.

LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit .

Company Contact

LifeMD, Inc.

Marc Benathen, CFO

Media Contact



EN
10/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIFEMD INC

 PRESS RELEASE

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscri...

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo Nordisk NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and suppo...

 PRESS RELEASE

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Pr...

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care....

 PRESS RELEASE

LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financia...

LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company’s current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition. “We are thrilled to wel...

 PRESS RELEASE

LifeMD Reports Fourth Quarter and Full Year 2025 Results

LifeMD Reports Fourth Quarter and Full Year 2025 Results Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels.Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth.Benefits infrastructure on track to cover approximately 220 million America...

 PRESS RELEASE

LifeMD to Participate in Two Investor Conferences During March

LifeMD to Participate in Two Investor Conferences During March NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March: Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside chat on Wednesday, March 18th at 9:00 a.m. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch